ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data kblankenship Sun, 08/30/2020 – 15:44

ESC: Novartis’ Entresto racks up a heart failure study win—but it’s a mixed one kblankenship Sat, 08/29/2020 – […]

ESC: AstraZeneca’s Farxiga cuts kidney disease risks by 39% in trial that could ‘rewrite’ the treatment textbook kblankenship […]

ESC: Pfizer, BMS’ Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study kblankenship […]

ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha kblankenship Fri, 08/28/2020 – 18:15

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT